Search results for "Pantoprazole"

showing 6 items of 6 documents

Effect of intravenous application of esomeprazole 40???mg versus pantoprazole 40???mg on 24-hour intragastric pH in healthy adults

2007

BACKGROUND: It has been demonstrated that therapy with proton pump inhibitors reduces recurrence of bleeding following initial endoscopic treatment of bleeding peptic ulcers. AIM: This study compared the effects of esomeprazole 40 mg and pantoprazole 40 mg on intragastric acid control. Both substances were administered intravenously as 15-min infusion and as bolus injection. METHODS: Healthy men and women volunteers were enrolled in this single-center, open, randomized, three-way crossover study. After administration of esomeprazole 40 mg and pantoprazole 40 mg intravenously as 15-min infusion, and pantoprazole 40 mg intravenously as bolus injection, continuous 24-h intragastric pH monitori…

AdultMalemedicine.medical_specialtymedicine.drug_classPepticProton-pump inhibitorPharmacologyGastroenterology2-PyridinylmethylsulfinylbenzimidazolesHelicobacter InfectionsEsomeprazoleGastric AcidInternal medicineHumansMedicineEsomeprazole SodiumInfusions IntravenousPantoprazoleMonitoring PhysiologicPantoprazoleCross-Over StudiesHelicobacter pyloriHepatologybusiness.industryStomachGastroenterologyEsomeprazoleGastric Acidity DeterminationHydrogen-Ion ConcentrationMiddle AgedAnti-Ulcer AgentsCrossover studymedicine.anatomical_structureInjections IntravenousBody ConstitutionGastric acidFemalebusinessmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct

Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer

1998

Background It is now clear that the extent to which gastric acid secretion must be suppressed varies with the clinical condition being treated. Aim To assess the 24-h control of gastric acidity and the individual response variability of three different doses of pantoprazole. Methods Sixty-four duodenal ulcer patients were recruited for this prospective, randomized, multicentre, double-blind, parallel-group study. They were subdivided into three well-matched groups treated with 20 mg o.m., 40 mg o.m. and 40 mg b.d. of pantoprazole, respectively. Endoscopy and intragastric pH monitoring were performed in each patient before and after 14 days of treatment. Results Fifty-five patients were elig…

Gastric Acidity Determinationmedicine.medical_specialtyChemotherapyHepatologyDosebusiness.industrymedicine.drug_classStomachmedicine.medical_treatmentGastroenterologyProton-pump inhibitorGastroenterologymedicine.anatomical_structurePharmacodynamicsInternal medicinemedicineGastric acidPharmacology (medical)businessPantoprazolemedicine.drugAlimentary Pharmacology & Therapeutics
researchProduct

The prognosis of patients having received optimal therapy for nonvariceal upper gastrointestinal bleeding might be worse in daily practice than in ra…

2010

International audience; BACKGROUND: Combination of endoscopic haemostatic and high-dose intravenous proton-pump inhibitors is considered to be the standard care for patients with acute peptic ulcer bleeding. AIM: This study assessed predictive factors of rebleeding and death in unselected patients presented to our hospital. METHODS: Consecutive patients with nonmalignant bleeding ulcers and stigmata of recent haemorrhage who received optimal treatment, between 22 August 2003 and 15 October 2007, were studied retrospectively. RESULTS: Among 140 included patients, 45 (32%) rebled and 30 received another haemostatic endoscopy, which was successful in 20 cases. In multivariate analysis, the onl…

MaleMultivariate analysisAdministration Oral2-Pyridinylmethylsulfinylbenzimidazoleslaw.inventionHospitals University0302 clinical medicineRandomized controlled trialRecurrenceRisk FactorslawOdds RatioHospital Mortality030212 general & internal medicineInfusions IntravenousPantoprazoleRandomized Controlled Trials as TopicAged 80 and overMortality rateHemostasis EndoscopicGastroenterologyMiddle AgedCombined Modality TherapyIntensive care unit3. Good healthIntensive Care UnitsPeptic Ulcer HemorrhageTreatment OutcomeInjections IntravenousFemale030211 gastroenterology & hepatologyFranceAdultmedicine.medical_specialtyRisk AssessmentYoung Adult03 medical and health sciencesInternal medicinemedicineHumansAgedRetrospective StudiesChi-Square DistributionHepatologybusiness.industryProton Pump Inhibitors[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyOdds ratiomedicine.disease[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyConfidence intervalSurgeryLogistic ModelsUpper gastrointestinal bleedingRockall scorebusiness
researchProduct

2020

There is evidence that intake of proton pump inhibitors (PPI) increases the risk for spontaneous bacterial peritonitis (SBP) in patients with liver cirrhosis. However, data regarding the impact of PPI intake on occurrence of infections other than SBP are still lacking.We hypothesized that PPI use is associated with a higher rate of infections other than SBP in patients with liver cirrhosis.The current case-control study sample included patients with liver cirrhosis from the Disease Analyzer database (IQVIA), which compiles data such as risk factors, drug prescriptions and diagnoses obtained from general practitioners and specialists in Germany. In total, 2,823 patients with infections were …

medicine.medical_specialtyCirrhosisRespiratory tract infectionsbusiness.industrymedicine.drug_classCase-control studyProton-pump inhibitorGeneral MedicineDiseasemedicine.diseaseGastroenterology03 medical and health sciences0302 clinical medicineSpontaneous bacterial peritonitis030220 oncology & carcinogenesisInternal medicineMedicine030212 general & internal medicinebusinessOmeprazolemedicine.drugPantoprazoleMedicine
researchProduct

A 10-day levofloxacin-based therapy in patients with resistant infection: A controlled trial

2004

Background & Aims: Antibiotic resistance is a major issue in anti– Helicobacter pylori treatment. This study was aimed at assessing the efficacy of 2 therapies in patients with resistant H pylori infection. Methods: Patients who had failed 1 or more eradication regimens underwent upper gastrointestinal endoscopy and 2 antral and 2 corpus biopsy specimens were taken for histology and culture. Metronidazole, clarithromycin, and amoxicillin resistance were determined by E-test. Patients were randomly assigned to 2 therapies: 1 group received pantoprazole 40 mg, amoxicillin 1 g, levofloxacin 250 mg, all twice daily for 10 days, and the other group was treated with omeprazole 20 mg twice daily f…

medicine.medical_specialtyHepatologybiologymedicine.diagnostic_testbusiness.industryUrea breath testGastroenterologyHelicobacter pyloriAmoxicillinbiology.organism_classificationGastroenterologySurgeryMetronidazoleLevofloxacinClarithromycinInternal medicinemedicinebusinessOmeprazolemedicine.drugPantoprazoleClinical Gastroenterology and Hepatology
researchProduct

Pantoprazole: from drug metabolism to clinical relevance.

2008

Conditions requiring inhibition of acid secretion, such as gastro-oesophageal reflux disease (GORD), peptic ulcers, non-ulcer dyspepsia or the use of NSAIDs, are very common, and their prevalence is expecting to rise as they are seen predominantly amongst the elderly. Among the drugs available to inhibit acid secretion, proton pump inhibitors (PPI) have been shown to have the best efficacy-safety ratio and have been used widely.This paper was intended to provide an overall presentation of one of these PPIs, pantoprazole.This study was first intended to give an overview of pantoprazole, so a Medline search was conducted using pantoprazole as unique search term, without publication date restr…

medicine.medical_specialtyPeptic UlcerPepticRabeprazoleLansoprazoleToxicologyGastroenterology2-PyridinylmethylsulfinylbenzimidazolesEsomeprazoleInternal medicinemedicineHumansPantoprazoleOmeprazolePantoprazolePharmacologyClinical Trials as Topicbiologybusiness.industryProton Pump InhibitorsGeneral MedicineHelicobacter pyloribiology.organism_classificationAnti-Ulcer Agentsdigestive system diseasesTreatment OutcomeGastroesophageal RefluxbusinessDrug metabolismmedicine.drugExpert opinion on drug metabolismtoxicology
researchProduct